We are live on ! Find out more
EP

Eversept Partners Portfolio holdings

AUM $1.93B
1-Year Est. Return 160.8%
This Fund
S&P 500
This Quarter Est. Return
-7.76%
1 Year Est. Return
+160.8%
3 Year Est. Return
+321.09%
5 Year Est. Return
+420.29%
10 Year Est. Return
–
AUM
$1.41B
AUM Growth
+$104M
Cap. Flow
+$94.2M
Cap. Flow %
6.7%
Top 10 Hldgs %
55.6%
Holding
106
New
20
Increased
33
Reduced
17
Closed
29

Top Buys

Rank Stock Value
1
SNY icon
Sanofi
SNY
+$46.7M
2
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$26.7M
3
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$26.5M
4
TNDM icon
Tandem Diabetes Care
TNDM
+$21M
5
ABMD
Abiomed Inc
ABMD
+$18.7M

Top Sells

Rank Stock Value
1
ASND icon
Ascendis Pharma A/S
ASND
+$49M
2
HCA icon
HCA Healthcare
HCA
+$27.9M
3
MASI
Masimo
MASI
+$27.2M
4
ARKG icon
ARK Genomic Revolution ETF
ARKG
+$21.6M
5
RCM
R1 RCM Inc. Common Stock
RCM
+$17.5M

Sector Composition

Rank Sector Weight
1 Healthcare 70.04%
2 Miscellaneous 29.08%
3 Industrials 0.88%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ABMD
26
DELISTED
Abiomed Inc
ABMD
$17.2M 1.22%
+69,297
New +$18.7M
NTRA icon
27
Natera
NTRA
$47B
$16.9M 1.2%
+475,655
New +$17.6M
GH icon
28
Guardant Health
GH
$21.7B
$16.4M 1.17%
406,375
+193,172
+91% +$9.57M
TNDM icon
29
Tandem Diabetes Care
TNDM
$1.49B
$15.2M 1.08%
+256,268
New +$21M
CLDX icon
30
Celldex Therapeutics
CLDX
$3.07B
$14.9M 1.06%
552,388
-84,065
-13% -$2.44M
XENE icon
31
Xenon Pharmaceuticals
XENE
$5.81B
$14.2M 1.01%
465,911
+55,890
+14% +$1.69M
RCM
32
DELISTED
R1 RCM Inc. Common Stock
RCM
$12.4M 0.88%
590,819
-770,687
-57% -$17.5M
MRVI icon
33
Maravai LifeSciences
MRVI
$1.14B
$12.1M 0.86%
+425,364
New +$13.5M
LNTH icon
34
Lantheus
LNTH
$6.58B
$11.9M 0.85%
+180,053
New +$11.4M
ALNY icon
35
Alnylam Pharmaceuticals
ALNY
$31.7B
$11.5M 0.82%
78,987
+26,116
+49% +$3.7M
MASS icon
36
908 Devices
MASS
$444M
$9.69M 0.69%
470,444
+253,295
+117% +$4.26M
LQDA icon
37
Liquidia Corp
LQDA
$6.06B
$9.15M 0.65%
2,099,708
+722,218
+52% +$3.73M
QGEN icon
38
Qiagen
QGEN
$8.9B
$8.96M 0.64%
179,093
-2,633
-1% -$128K
IWM icon
39
PUT
iShares Russell 2000 ETF
IWM
$80.8B
$8.47M 0.6%
+50,000
New +$9.22M
TARO
40
DELISTED
Taro Pharmaceutical Industries Ltd.
TARO
$7.97M 0.57%
220,390
+104
+0% +$3.96K
HQY icon
41
HealthEquity
HQY
$7.97B
$7.8M 0.55%
127,043
-17,097
-12% -$1.1M
MRUS
42
DELISTED
Merus
MRUS
$6.52M 0.46%
287,806
+210,957
+275% +$4.4M
ILMN icon
43
Illumina
ILMN
$32.6B
$6.5M 0.46%
36,253
-3,591
-9% -$917K
HUM icon
44
Humana
HUM
$46.3B
$5.24M 0.37%
+11,170
New +$4.97M
RDUS
45
DELISTED
Radius Health, Inc.
RDUS
$5.21M 0.37%
502,587
+200,415
+66% +$1.49M
CLDX icon
46
CALL
Celldex Therapeutics
CLDX
$3.07B
$5.17M 0.37%
+191,600
New +$5.56M
VRDN icon
47
Viridian Therapeutics
VRDN
$2.61B
$5.16M 0.37%
445,592
+289,849
+186% +$3.9M
FOLD
48
DELISTED
Amicus Therapeutics
FOLD
$5.14M 0.37%
+478,245
New +$3.94M
MRK icon
49
CALL
Merck
MRK
$366B
$4.44M 0.32%
48,700
– –
PBYI icon
50
Puma Biotechnology
PBYI
$468M
$4.09M 0.29%
1,435,077
+10,427
+0.7% +$25.9K
1
2
3 4 5

Similar funds

SWM
Segment Wealth Management Houston, Texas $1.93B AUM 29.24% 1-Year Est. Return
RIA
Regal Investment Advisors Kentwood, Michigan $1.92B AUM 23.13% 1-Year Est. Return
SI
Standard Investments New York $1.93B AUM 6.23% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $1.92B AUM 45.54% 1-Year Est. Return
DCP
Distillate Capital Partners Chicago, Illinois $1.92B AUM 5.31% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
GIA
Guyasuta Investment Advisors Pittsburgh, Pennsylvania $1.94B AUM 32.92% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return

Eversept Partners's Q2 2022 Portfolio in Review

As of Q2 2022, Eversept Partners held 106 positions worth $1.41B, up 8% from $1.3B the previous quarter. Its ten largest holdings account for 56% of the portfolio.

Eversept Partners deployed $94.2M of net new capital in Q2 2022, opening 20 new positions and adding to 33 existing holdings. Its largest new stake was Sanofi: 879,460 shares worth $44M.

By sector, the portfolio is most concentrated in Healthcare at 70% of assets, down from 79% a quarter earlier, followed by Miscellaneous and Industrials.

On the sell side, the largest reduction was Masimo, an estimated $27.2M trimmed.

  • Eversept Partners's largest Q2 2022 buy was Sanofi: 879,460 shares worth $44M.
  • Eversept Partners added most to Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2022, an estimated $26.5M increase.
  • Eversept Partners's biggest Q2 2022 reduction was Masimo, cutting an estimated $27.2M.
  • Eversept Partners fully exited Ascendis Pharma A/S in Q2 2022, selling an estimated $49M.
  • Eversept Partners's ten largest holdings make up 56% of its $1.41B portfolio in Q2 2022.
  • Eversept Partners opened 20 new positions and closed 29 in Q2 2022.
  • Eversept Partners's portfolio value rose 8% quarter-over-quarter to $1.41B.

Based on Eversept Partners's 13F filing for Q2 2022, filed 15 Aug 2022.